Media Center

CLSI 2019 Q3 CONNECTIONS – Read More


FAST Companies

  • YourChoice Therapeutics (FAST Fall ’18) CSO Nadja Mannowetz was featured in Freakonomics Radio speaking on the advantages of male contraceptives Listen Here
  • Encellin (FAST Spring ’17) featured in FierceBiotech news: “Y Combinator startup pursuing ‘scarless’ pouch for cell transplants in diabetes.” Read More
  • Inflammatix (FAST Fall ’17) received American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award for its rapid HostDx™ tests Read More
  • Siolta Therapeutics (FAST Fall ’17) joins the Microbiome Therapeutics Innovation Group (MTIG) Read More
  • SciBac (FAST Fall ’16) was featured in San Francisco Business Times article: New antibiotics desperately needed for rising tide of drug-resistant ‘superbugs’ Read More | SciBac also received an NIH grant for the treatment of lung infections associated with cystic fibrosis Read More
  • GigaGen (FAST Spring ’15) was listed as 1 of 6 award-winning life science companies in the Bay Area by BioSpace Read More
  • Magnetic Insight (FAST Spring ’15) announced corporate expansion headquarters move to a new state-of-the-art 22,000 square-foot facility in Alameda, CA Read More
  • Purigen Biosystems (FAST Spring ‘15) raised a $26.4 million Series B financing to accelerate commercialization of automated sample preparation platform Read More
  • Whole Biome (FAST Spring ’14) secured $35M in Series B financing, led by Sequoia Capital Read More and just announced positive clinical results showing the efficacy of its proprietary microbiome Live SynbioticsTM formulation in improving glucose control in patients w/ T2D Read More
  • ProteinQure, a graduate of the first FAST CTA collaboration with the Canadian Consulate, has just raised a $4M see round to unlock the potential of protein therapeutics Read More


  • CARB-X Strengthens Leadership Team with Appointment of Erin Duffy as Chief of Research and Development (R&D) Read More
  • CARB-X awards Oxford Drug Design funding to develop a new class of antibiotics to treat drug-resistant Gram-negative infections Read More
  • CARB-X funds Debiopharm to develop a new class of antibiotics to treat hospital-acquired pneumonia caused by multidrug-resistant superbug Acinetobacter baumannii Read More
  • CARB-X funds BB100, a subsidiary of Bravos Biosciences, to develop a unique monoclonal antibody to prevent and treat hyper-virulent multi-drug-resistant E. coli infections Read More
  • CARB-X funds Integrated Biotherapeutics to expand the development of its Staphylococcus aureus vaccine to facilitate use in the developing world Read More
  • CARB-X funds Vaxxilon AG to develop a new vaccine to prevent carbapenem-resistant superbug Klebsiella pneumoniae infections Read More
  • CARB-X funds SutroVax to develop a new vaccine to prevent Group A Streptococcal infections Read More


CLSI/CLSA events

  • 10/16 | San Diego, CLSA Bio in the Brewery Happy Hour
  • 10/17 | San Carlos, CLSI Startup Buzz Networking Event
  • 10/23 | San Francisco, CLSA Bio in the Bay
  • 11/15 | San Francisco, 16th Annual Pantheon DiNA Awards

Community Events

  • 9/12 | San Francisco, Rosenman D-Series: Tony Fields. “The Full Picture: Why FDA Approval Depends on More Than Your Clinical Trial”
  • 9/17 | South San Francisco, JLABS: Meet with NCI
  • 9/17 | San Francisco, QB3 Seminar: Ira Mellman, Drug Discovery & Development in Cancer Immunology
  • 9/19 | San Francisco, UCSF Entrepreneurship Center: NIH Guest Lecture: Accessing Government Funds for your Startup
  • 9/20 | San Francisco, Deadline to Apply for QB3 Biotech/Biopharma Pitch Summit
  • 9/24 | South San Francisco, JLABS: Meet with BARDA
  • 9/26 | San Francisco, Fall 2019 SBIR Workshop at UCSF Mission Bay
  • 10/2| Berkeley, Fall 2019 SBIR Workshop at Berkeley
  • 10/2-6 | Washington DC, IDWeek 2019
  • 10/3 | San Francisco, QB3 Seminar: David Spellmeyer, Score! How Your SBIR/STTR Application is Reviewed and Scored
  • 10/9 | South San Francisco, JLABS: Meet with Venrock
  • 10/11 | San Francisco, Rosenman D-Series: Neil Tiwari, dRx Capital
  • 10/11-13 | San Francisco, UCSF Rosenman Institute MIT Hacking Medicine Grand Hack
  • 10/29 | South San Francisco, JLABS: Meet with 5AM Ventures
  • 10/31 | San Francisco, QB3 Seminar: Tito Serafini, Lessons Learned at Atreca from Founding Through IPO
  • 11/8 | Submission Deadline to Apply for 5th Annual CA JumpStart Grant